Literature DB >> 15700135

Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression.

J Boucher1, D Quilliot, J P Pradères, M F Simon, S Grès, C Guigné, D Prévot, G Ferry, J A Boutin, C Carpéné, P Valet, J S Saulnier-Blache.   

Abstract

AIMS/HYPOTHESIS: Autotaxin is a lysophospholipase D that is secreted by adipocytes and whose expression is substantially up-regulated in obese, diabetic db/db mice. The aim of the present study was to depict the physiopathological and cellular mechanisms involved in regulation of adipocyte autotaxin expression.
METHODS: Autotaxin mRNAs were quantified in adipose tissue from db/db mice (obese and highly diabetic type 2), gold-thioglucose-treated (GTG) mice (highly obese and moderately diabetic type 2), high-fat diet-fed (HFD) mice (obese and moderately diabetic type 2), streptozotocin-treated mice (thin and diabetic type 1), and massively obese humans with glucose intolerance.
RESULTS: When compared to non-obese controls, autotaxin expression in db/db mice was significantly increased, but not in GTG, HFD, or streptozotocin-treated mice. During db/db mice development, up-regulation of autotaxin occurred only 3 weeks after the emergence of hyperinsulinaemia, and simultaneously with the emergence of hyperglycaaemia. Adipocytes from db/db mice exhibited a stronger impairment of insulin-stimulated glucose uptake than non-obese and HFD-induced obese mice. Autotaxin expression was up-regulated by treatment with TNFalpha (insulin resistance-promoting cytokine), and down-regulated by rosiglitazone treatment (insulin-sensitising compound) in 3T3F442A adipocytes. Finally, adipose tissue autotaxin expression was significantly up-regulated in patients exhibiting both insulin resistance and impaired glucose tolerance. CONCLUSIONS/
INTERPRETATION: The present work demonstrates the existence of a db/db-specific up-regulation of adipocyte autotaxin expression, which could be related to the severe type 2 diabetes phenotype and adipocyte insulin resistance, rather than excess adiposity in itself. It also showed that type 2 diabetes in humans is also associated with up-regulation of adipocyte autotaxin expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15700135      PMCID: PMC1885462          DOI: 10.1007/s00125-004-1660-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  13 in total

Review 1.  Lysophosphatidic acid signaling: how a small lipid does big things.

Authors:  Celine Luquain; Vicki A Sciorra; Andrew J Morris
Journal:  Trends Biochem Sci       Date:  2003-07       Impact factor: 13.807

Review 2.  Adipose tissue as an endocrine organ: impact on insulin resistance.

Authors:  I M Jazet; H Pijl; A E Meinders
Journal:  Neth J Med       Date:  2003-06       Impact factor: 1.422

3.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.

Authors: 
Journal:  Diabetes Care       Date:  1997-07       Impact factor: 19.112

4.  Semicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes.

Authors:  N Morin; J M Lizcano; E Fontana; L Marti; F Smih; P Rouet; D Prévot; A Zorzano; M Unzeta; C Carpéné
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

5.  Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis.

Authors:  Stéphane Gesta; Marie-Françoise Simon; Astrid Rey; David Sibrac; Alexia Girard; Max Lafontan; Philippe Valet; Jean Sébastien Saulnier-Blache
Journal:  J Lipid Res       Date:  2002-06       Impact factor: 5.922

6.  Increased formation of lysophosphatidic acids by lysophospholipase D in serum of hypercholesterolemic rabbits.

Authors:  Akira Tokumura; Yumi Kanaya; Masaki Kitahara; Maki Miyake; Yasuko Yoshioka; Kenji Fukuzawa
Journal:  J Lipid Res       Date:  2002-02       Impact factor: 5.922

7.  Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity.

Authors:  Gilles Ferry; Edwige Tellier; Anne Try; Sandra Grés; Isabelle Naime; Marie Françoise Simon; Marianne Rodriguez; Jérémie Boucher; Ivan Tack; Stéphane Gesta; Pascale Chomarat; Marc Dieu; Martine Raes; Jean Pierre Galizzi; Philippe Valet; Jean A Boutin; Jean Sébastien Saulnier-Blache
Journal:  J Biol Chem       Date:  2003-03-17       Impact factor: 5.157

8.  Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase.

Authors:  Akira Tokumura; Eiji Majima; Yuko Kariya; Kyoko Tominaga; Kentaro Kogure; Katsuhiko Yasuda; Kenji Fukuzawa
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

Review 9.  Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha.

Authors:  Hong Ruan; Harvey F Lodish
Journal:  Cytokine Growth Factor Rev       Date:  2003-10       Impact factor: 7.638

10.  Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.

Authors:  Makiko Umezu-Goto; Yasuhiro Kishi; Akitsu Taira; Kotaro Hama; Naoshi Dohmae; Koji Takio; Takao Yamori; Gordon B Mills; Keizo Inoue; Junken Aoki; Hiroyuki Arai
Journal:  J Cell Biol       Date:  2002-07-15       Impact factor: 10.539

View more
  45 in total

1.  Depot-specific regulation of autotaxin with obesity in human adipose tissue.

Authors:  Chloé Rancoule; Rodolphe Dusaulcy; Karine Tréguer; Sandra Grès; Charlotte Guigné; Didier Quilliot; Philippe Valet; Jean Sébastien Saulnier-Blache
Journal:  J Physiol Biochem       Date:  2012-05-27       Impact factor: 4.158

Review 2.  Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease.

Authors:  David Y Hui
Journal:  Curr Opin Lipidol       Date:  2016-10       Impact factor: 4.776

Review 3.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

4.  Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts.

Authors:  Abby L Parrill; Daniel L Baker
Journal:  Expert Opin Ther Pat       Date:  2010-11-04       Impact factor: 6.674

5.  Altered food consumption in mice lacking lysophosphatidic acid receptor-1.

Authors:  R Dusaulcy; D Daviaud; J P Pradère; S Grès; Ph Valet; J S Saulnier-Blache
Journal:  J Physiol Biochem       Date:  2009-12       Impact factor: 4.158

Review 6.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

Review 7.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

8.  Autotaxin-LPA signaling contributes to obesity-induced insulin resistance in muscle and impairs mitochondrial metabolism.

Authors:  Kenneth D'Souza; Carine Nzirorera; Andrew M Cowie; Geena P Varghese; Purvi Trivedi; Thomas O Eichmann; Dipsikha Biswas; Mohamed Touaibia; Andrew J Morris; Vassilis Aidinis; Daniel A Kane; Thomas Pulinilkunnil; Petra C Kienesberger
Journal:  J Lipid Res       Date:  2018-08-02       Impact factor: 5.922

9.  Adipose Tissue Lipokines: Recent Progress and Future Directions.

Authors:  Veronica L Li; Joon T Kim; Jonathan Z Long
Journal:  Diabetes       Date:  2020-12       Impact factor: 9.461

10.  Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

Authors:  Marion David; Estelle Wannecq; Françoise Descotes; Silvia Jansen; Blandine Deux; Johnny Ribeiro; Claire-Marie Serre; Sandra Grès; Nathalie Bendriss-Vermare; Mathieu Bollen; Simone Saez; Junken Aoki; Jean-Sébastien Saulnier-Blache; Philippe Clézardin; Olivier Peyruchaud
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.